GKGrażyna Kurzawińska

Grażyna Kurzawińska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grażyna Kurzawińska has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associations of IL-2, IL-6 and IL-10 Gene Polymorphisms with Biochemical Parameters and Calcineurin Inhibitor Dosing in Kidney Transplant Recipients

    by Anna Bogacz, Paweł Szakoła, Monika Kuciak, Jerzy Sieńko, Maciej Kotowski, Grażyna Kurzawińska, Wojciech ŁabęDź, Aleksandra E. Mrozikiewicz, Agata Urbaniak, Piotr Olbromski, et al.

    Background/Objectives: Kidney graft dysfunction remains a major challenge limiting long-term transplant survival despite advances in immunosuppressive therapy. Cytokine signaling pathways have been implicated in the regulation of alloimmune responses and chronic inflammation, but their contribution to long-term graft function and immunosuppressant pharmacokinetics remains incompletely understood. This study investigated associations among selected cytokine gene polymorphisms (IL-2 −330T>G, IL-6 −174G>C, and IL-10 −1082A>G), biochemical and hematological parameters, and calcineurin inhibitor (tacrolimus and cyclosporine) dosing in kidney transplant recipients. Methods: A total of 394 kidney transplant recipients receiving tacrolimus or cyclosporine were enrolled. Genotyping of IL-2 rs2069762, IL-6 rs1800795 and IL-10 rs1800896 was performed using real-time PCR. Clinical, biochemical, and pharmacokinetic data were analyzed using univariate and multivariate statistical models adjusted for relevant demographic and clinical covariates. Results: IL-2 rs2069762 and IL-6 rs1800795 polymorphisms were not associated with clinically relevant differences in biochemical parameters, calcineurin inhibitor dosing, or transplant outcomes. For IL-10 rs1800896, no statistically significant associations were observed with cyclosporine A blood levels, dose, or C/D ratio. Among tacrolimus-treated patients, the regression model for the C/D ratio was borderline significant (F(2,207) = 3.048, p = 0.050, R2 = 0.029). However, the genotype-specific association for the heterozygous GA genotype versus AA was not statistically significant in the unadjusted model (B = −0.462, 95% CI: −0.97 to 0.04, p = 0.072) or after adjustment for age, sex, and time since transplantation (B = −0.450, 95% CI: −0.95 to 0.05, p = 0.078). Although univariate analyses identified associations between IL-10 rs1800896 and selected biochemical parameters, these findings were not confirmed in multivariable models. No significant associations were observed between the analyzed cytokine polymorphisms and graft rejection, graft survival, patient survival, or clinically relevant markers of kidney graft function. Conclusions: The results suggest a possible, although not statistically significant, association between IL-10 rs1800896 and tacrolimus exposure, as assessed by the C/D ratio. This observation should be considered preliminary and interpreted with caution. The lack of CYP3A5 genotyping and functional assessment of IL-10 activity, inflammation, and CYP3A-dependent metabolism further limits the interpretation of this potential association. Larger prospective studies with comprehensive pharmacogenetic and functional characterization are needed to determine whether IL-10 rs1800896 contributes to interindividual variability in tacrolimus exposure and whether it may have potential applications in individualized immunosuppressive therapy.

  • Open Access

    Genetic Variations in the Fibronectin 1 Gene (FN1) and Risk of Female Reproductive Cancers—A Preliminary Study

    by Piotr Pawlik, Grażyna Kurzawińska, Marcin Ożarowski, Tomasz M. Karpiński, Anna Bogacz, Piotr J. Olbromski, Aleksandra E. Mrozikiewicz, Maciej Brązert, Wiesław Markwitz, Agnieszka Seremak-Mrozikiewicz

    We investigated five single-nucleotide variants (SNVs) of the FN1 gene in female reproductive organ cancers. The proteins expressed by this gene are essential components of the extracellular matrix (ECM) that constitutes the tumor microenvironment (TME). The study group included 208 women diagnosed with cervical, uterine, and ovarian cancers and 208 age-matched cancer-free controls. Genomic DNA from whole blood was used to analyze five intronic SNVs of the FN1 gene using PCR/RFLP. The results indicate that two of the studied FN1 gene variants may increase the risk of gynecological cancers in dominant and log-additive models (p = 0.048 and p = 0.040 for rs6725958, p = 0.033 and p = 0.038 for rs1968510, respectively). Comparing individual cancer groups with the controls, differences were observed for the ovarian cancer group (rs1968510 p = 0.015 and p = 0.016, rs6725958 p = 0.070 and p = 0.037 in dominant and log-additive models, respectively). None of these associations remained statistically significant after Bonferroni correction for multiple testing. Haplotype analyses revealed that the AGATC haplotype, containing minor alleles for rs35343655 and rs6725958, was more frequent in the entire gynecological cancer group (p = 0.0036). For individual cancer types, values of p = 0.0071 for ovarian, p = 0.0028 for endometrial, and p = 0.0269 for cervical cancers were obtained; Our preliminary study suggests that the rs6725958 and rs1968510 FN1 variants may slightly increase the risk of female reproductive system cancers, particularly ovarian cancer. These findings require further validation in larger, independent cohorts and functional studies.


  • Open Access

    Association of Gene Variants in Matrix Metalloproteinases and Their Tissue Inhibitors with Intraventricular Haemorrhage in Preterm Infants

    by Dawid Szpecht, Karolina Żyto, Gabriela Ciszek, Karolina Duczmal, Zofia Kowal, Kornelia KręCiszewska, Zuzanna Słowińska, Grażyna Kurzawińska, Anna Sowińska, Agnieszka Seremak-Mrozikiewicz

    The objective of the present study is to examine the association between the presence of various forms of matrix metalloproteinase genes (MMP-1, MMP-9, TIMP-1 and TIMP-2) and their tissue inhibitors, and the incidence of intraventricular haemorrhage (IVH) in premature neonates. The data for this study were obtained from samples of peripheral venous blood, which were collected and stored post-delivery. The techniques employed for the purpose of genotyping were polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP). The population that was examined comprised 100 patients with a gestational age (GA) ranging from 22 to 33 weeks and birth weight (BW) ranging from 432 to 2100 g. In the cohort of enrolled patients, 48 cases of IVH were observed. As indicated by the findings of this study, the majority of observed correlations between MMP-1, MMP-9, TIMP-1, and TIMP-2 variants and IVH did not demonstrate statistical significance, with the exception of the T allele of TIMP1 rs4898. Nevertheless, the findings of this study indicated a potential impact of these variants on the incidence of IVH. The present study suggests that further research is required to elucidate the role of MMP/TIMP polymorphisms in the aforementioned disease.

  • Open Access

    Analysis of the Role of Gene Variants in Matrix Metalloproteinases and Their Tissue Inhibitors in Bronchopulmonary Dysplasia (BPD): A Study in the Polish Population

    by Dawid Szpecht, Kareem Abu-Amara, Grażyna Kurzawinska, Agnieszka Seremak-Mrozikiewicz

    This study aimed to explore the association between genetic variants of matrix metalloproteinases (MMP-1 rs1799750, MMP-9 rs17576, and rs17577) and their tissue inhibitors (TIMP-1 rs4898, TIMP-2 rs2277698, and rs55743137) in the development of bronchopulmonary dysplasia (BPD) in infants from a Polish population. Methods: A cohort consisting of 100 premature infants (47% female) was analyzed, in which there were 38 BPD cases and 62 controls without BPD. Genotype distributions were analyzed, and their relationship with BPD risk was assessed after adjustment for potential confounders. Results: Application of Bonferroni correction for multiple testing showed that none of the single-nucleotide polymorphisms (SNPs) reached the adjusted significance threshold (p < 0.008). However, analysis of allele frequencies using adjusted p-values identified a statistically significant difference for MMP1 rs17999750 (p = 0.038). Conclusion: These findings do not support a significant role of TIMP-2 and MMP-9 genetic variations in the pathogenesis of BPD among preterm infants. While these results are informative, a limitation of this study is the small sample size, and larger studies are needed to confirm these observations.


  • Open Access

    Prostaglandin Pathway Polymorphisms and HsPDA Treatment Outcomes in Preterm Infants below 32 Weeks: Pilot Study

    by Marcin Minta, Grażyna Kurzawińska, Zuzanna Banach Minta, Agnieszka Seremak Mrozikiewicz, Dawid Szpecht

    Background: Despite substantial advances in neonatology, the management of patent ductus arteriosus (PDA) in preterm infants continues to pose a major clinical challenge. The presence of PDA may exacerbate circulatory instability, contribute to tissue hypoxia, and significantly increase the risk of prematurity-related complications. Risk factors for patent ductus arteriosus (PDA), including its hemodynamically significant form (HsPDA), have been consistently associated with lower gestational age, low birth weight, the requirement for invasive mechanical ventilation, and lack of antenatal corticosteroid exposure. With the advent of novel diagnostic approaches, growing attention has been directed toward the genetic determinants of various neonatal conditions. Genetic variability has been extensively documented as a factor influencing drug metabolism, thereby modulating dose-dependent responses and resistance to standard pharmacological interventions. Methods: The study population comprised neonates delivered before 32 completed weeks’ gestation to assess the potential impact of polymorphisms in genes associated with the prostaglandin pathway on the response to pharmacological treatment of HsPDA. Results: Among the identified polymorphisms, one demonstrated a statistically significant association with treatment success. Additional analyses were performed to determine whether therapeutic efficacy differed according to the drug administered. Conclusions: We propose that further research, particularly studies incorporating diverse ethnic populations, may provide valuable insights into the underlying the pathophysiology of PDA and contribute to the development of more effective treatment strategies.

  • Open Access

    Association Between Genetic Polymorphisms in the Prostaglandin Pathway and the Development of Patent Ductus Arteriosus in Preterm Infants

    by Marcin Minta, Grażyna Kurzawińska, Zuzanna-Banach Minta, Agnieszka Seremak Mrozikiewicz, Dawid Szpecht

    Patent ductus arteriosus (PDA) constitutes a significant clinical condition, frequently associated with a spectrum of complications that may profoundly compromise the health status of neonates, particularly those born preterm. Multiple predisposing factors—including prematurity, low birth weight, and respiratory insufficiency—have been consistently documented in the scientific literature. In this study, we investigated the influence of genetic polymorphisms in genes associated with the arachidonic acid–prostaglandin metabolic pathway. Specifically, we analyzed polymorphisms in genes encoding phospholipase A2 (rs10798059, rs1549637, rs4375, rs1805017, rs1051931), cyclooxygenase-1 (rs1236913), prostaglandin synthase 2 (rs13283456), and the prostaglandin E2 receptor EP4 (rs4613763). The study cohort comprised 99 preterm neonates born between 24 and 32 weeks of gestation. Genetic analyses were performed to identify polymorphisms in the aforementioned genes. Statistical evaluation demonstrated that selected polymorphic were significantly associated with an increased risk of patent ductus arteriosus development. This study represents a preliminary step toward elucidating the contribution of genetic variability to the pathogenesis of patent ductus arteriosus. Improved understanding of these molecular mechanisms may facilitate the early identification of neonates at increased risk and support the implementation of targeted monitoring and preventive strategies in this high-risk population.

  • Open Access

    Association Between Genetic Polymorphisms in the Prostaglandin Pathway and the Development of Patent Ductus Arteriosus in Preterm Infants

    by Marcin Minta, Grażyna Kurzawińska, Zuzanna Banach-Minta, Agnieszka Seremak Mrozikiewicz, Dawid Szpecht

    Patent ductus arteriosus (PDA) constitutes a significant clinical condition, frequently associated with a spectrum of complications that may profoundly compromise the health status of neonates, particularly those born preterm. Multiple predisposing factors—including prematurity, low birth weight, and respiratory insufficiency—have been consistently documented in the scientific literature. In this study, we investigated the influence of genetic polymorphisms in genes associated with the arachidonic acid–prostaglandin metabolic pathway. Specifically, we analyzed variants in genes encoding phospholipase A2 (rs10798059, rs1549637, rs4375, rs1805017, rs1051931), cyclooxygenase-1 (rs1236913), prostaglandin synthase 2 (rs13283456), and the prostaglandin E2 receptor EP4 (rs4613763). The study cohort comprised 99 preterm neonates born between 24 and 32 weeks of gestation. Genetic analyses were performed to identify polymorphisms in the aforementioned genes. Statistical evaluation demonstrated that selected polymorphic variants were significantly associated with an increased risk of patent ductus arteriosus development. This study represents a preliminary step toward elucidating the contribution of genetic variability to the pathogenesis of patent ductus arteriosus. Improved understanding of these molecular mechanisms may facilitate the early identification of neonates at increased risk and support the implementation of targeted monitoring and preventive strategies in this high-risk population.

  • Open Access

    Polymorphic Variants of Selected Genes Regulating Bile Acid Homeostasis in Women with Intrahepatic Cholestasis of Pregnancy

    by Krzysztof Piątek, Grażyna Kurzawińska, Marcin Ożarowski, Piotr Józef Olbromski, Adam Kamiński, Maciej Brązert, Tomasz M. Karpiński, Wiesław Markwitz, Agnieszka Seremak-Mrozikiewicz

    Intrahepatic cholestasis of pregnancy (ICP) is characterized by the onset of pruritus and elevated serum transaminases and bile acids (BA). The key enzyme in BA synthesis is CYP7A1, and its functions are regulated by various nuclear receptors. The goal of this study is to evaluate the association between CYP7A1, NR1H1, RXRA, and PPARA gene variants and risk of ICP. Five single nucleotide variants (SNVs), rs3808607 (CYP7A1), rs56163822 (NR1H4), rs1800206 (PPARA), rs749759, and rs11381416 (NR2B1), were genotyped in a group of 96 ICP and 211 controls. The T allele of the CYP7A1 (rs3808607) variant may be a protective factor against ICP risk (OR = 0.697, 95% CI: 0.495–0.981, p = 0.038). Genetic model analysis showed that rs3808607 was associated with decreased risk of ICP under dominant (OR = 0.55, 95% CI: 0.32–3.16, p = 0.032, AIC = 380.9) and log-additive models (OR = 0.71, 95% CI: 0.51–1.00, p = 0.046, AIC = 381.4). The A insertion in the rs11381416 NR2B1 variant was associated with the degree of elevation in the liver function tests TBA (34.3 vs. 18.8 μmol/L, p = 0.002), ALT (397.0 vs. 213.0 IU/L, p = 0.017), and AST (186.0 vs. 114.4 IU/L, p = 0.032) in ICP women. Results indicate an association between the CYP7A1 rs3808607 and the risk of ICP and the association of the rs11381416 of the NR2B1 receptor with higher values of liver function tests in women with ICP. A better understanding of the cooperation of proteins involved in BA metabolism may have important therapeutic implications in ICP and other hepatobiliary diseases.


  • Open Access

    The Importance of Gene Variants Related to Folate Uptake and Distribution in the Etiology of Recurrent Miscarriage and Intrauterine Fetal Demise

    by Martyna Kozłowska-Wytyk, Grażyna Kurzawińska, Marcin Ożarowski, Aleksandra E. Mrozikiewicz, Piotr Olbromski, Tomasz M. Karpiński, Bogusław Czerny, Hubert Wolski

    (1) Background: The study involves an assessment of the frequency of selected gene variants related to folate uptake and distribution (FOLR1 rs2071010, rs630074, FOLH1 rs61886492, GGH rs11545078, rs3758149 and SLC19A1 rs1051266) in a group of women with fetal demise in the Polish population. (2) Methods: A total of 310 subjects were enrolled in the study. There were 110 females with idiopathic recurrent miscarriages (RM), 80 with stillbirth (IUFD) and 120 healthy controls. Designated SNVs were determined by using PCR-RFLP methods. The difference in fetal demise prevalence was assessed using a chi-square test and logistic regression analysis. (3) Results: The rs630074 variant of the FOLR1 gene is associated with a statistically significant increase in the risk of IUFD in a recessive model (OR = 2.03, 95%CI: 1.06–3.90, p = 0.033). The rs61886492variant f FOLH1 is linked to an increased risk of IUFD in co-dominant (p = 0.030), dominant (OR = 2.62, 95%CI: 1.07–6.38, p = 0.032) and log-additive models (OR = 2.64, 95%CI: 1.15–6.06 p = 0.030). In female carriers of the A allele, the risk of IUFD was 2.8 times higher compared to the control group. No relationship between the mother’s genotype and the newborn’s birth weight or placental weight was observed for the studied SNVs. (4) Conclusions: Our study finds that the rs61886492 variant of the FOLH1 gene is associated with IUFD in Polish women. However, pregnancy failures have a multifactorial pathology and other genetic or environmental factors may also contribute to their complex etiology. Further research, preferably with larger groups of women from different ethnic backgrounds, is needed to confirm the results of the current study.


  • Open Access

    Up-regulated mRNA expression of VEGFA receptors (FLT1 and KDR) in placentas after assisted reproductive technology fertilization

    by Aleksandra E. Mrozikiewicz, Grażyna Kurzawińska, Michał Walczak, Marzena Skrzypczak-Zielińska, Marcin Ożarowski, Piotr Jędrzejczak

    Placental angiogenesis is a pivotal process for feto-maternal circulation and ensures efficient development of the placenta throughout pregnancy. Many factors during in vitro fertilization and embryo transfer procedures may affect placental gene expression and fetus development. The present study aimed to identify differences in angiogenesis-related gene (VEGFA, FGF2, FLT1, and KDR) expression profiles in placentas after assisted reproductive technology fertilization and natural conception in healthy women. In a case-control study, term placentas were collected from Caucasian women after assisted reproductive technology fertilization (N = 20) and after natural conception in women with uncomplicated pregnancy (N = 9). The mRNA expression in placentas was examined for VEGFA, FGF2, FLT1, and KDR genes by real-time quantitative polymerase chain reaction (RT-qPCR). Group stratification was performed for comparison of investigated genes between the type of embryo transferred (fresh/frozen), place of tissue donation (center/margin), and newborns’ gender (male/female). In the ART placentas, significant down-regulation of VEGFA gene (p = 0.016) and up-regulation of FLT1 (p = 0.026) and KDR (p < 0.001) gene receptors were observed. Genes encoding VEGFA receptors were up-regulated in both fresh (ET) and frozen (FET) embryo transfer groups compared to controls. For the FLT1 gene, a statistically significant difference was observed between the frozen embryo transfer group and the controls (p = 0.032). Relative expression of KDR was significantly higher for both embryo transfer groups compared to controls (p < 0.001) and between ET and FET (p = 0.002). No statistically significant differences were observed between placental expression in different places of tissue donation and newborns’ gender. We observed differences in the placental expression of VEGFA and its receptors FLT1 and KDR in pregnancies after assisted reproductive technology compared to naturally conceived pregnancies. More research is needed to clarify these alterations that may affect placental development and fetal health.